Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

Asthma Clinical Trial

Official title:

Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02260492
• Other study ID #: OTT329/305
• Status: Completed
• Phase: Phase 1
• First received: October 6, 2014
• Last updated: May 26, 2016
• Start date: September 2014
• Est. completion date: July 2015

Study information

• Verified date: May 2016
• Source: Oriel Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a study to establish the equivalence of OT329 Solis and Advair Diskus when administered by inhalation in patients with asthma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 879
• Est. completion date: July 2015
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males and females = 18 years old of non-child bearing potential or of child bearing potential committing to consistent and correct use of an acceptable method of birth control

2. Subjects with a reliable clinical history of asthma documented at least 12 weeks prior to screening

3. Subjects with a pre-bronchodilator FEV1 of > 40% and <85% of the predicted value during the screening visit and on the first day of treatment

4. Subjects who are currently non-smoking and have not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and had < 10 pack-years of historical use

5. Subjects with > 15% reversibility of FEV1 within 30 minutes following 360 mcg of albuterol inhalation (pMDI). Note: This test may be repeated on a different day if the patient fails the first attempt; and if the patient achieves at least 10% reversibility and the Investigator thinks that a second attempt is appropriate

6. Subjects who are able to discontinue their asthma medications (inhaled corticosteroids and long-acting beta agonists) during the run-in period and for the remainder of the study

7. Subjects who are able to replace current short-acting beta agonists (SABAs) with salbutamol/albuterol inhaler for use as needed for the duration of the study (subjects should be able to withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on study visits)

8. Subjects who are able to continue the following medications without a significant adjustment of dosage, formulation, or dosing interval for the duration of the study, and judged able by the investigator to withhold them for the specified minimum time intervals prior to each clinic visit: short-acting forms of theophylline for 12 hours, twice-a-day controlled release forms of theophylline for 24 hours, once-a-day controlled-release forms of theophylline for 36 hours

9. Subjects who are able to discontinue the following medications for the specified minimum time intervals prior to the run-in period and for the remainder of the study: oral and parenteral corticosteroids for 1 month and oral short-acting beta agonists for 12 hours

10. Subjects who are able and willing to give their written informed consent to participate in the study.

**********************************************************

Exclusion Criteria:

11. Female Subjects who are pregnant or breastfeeding

12. Subjects who have life-threatening asthma in the last 10 years, as defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnoea; respiratory arrest or hypoxic seizures, asthma-related syncopal episodes(s), or hospitalizations within the past year or during the run-in period

13. Subjects with evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbated during the study

14. Subjects with a hypersensitivity to any sympathomimetic drug (e.g. Salmeterol or salbutamol/albuterol) or any inhaled, intranasal or systemic corticosteroid therapy

15. Subjects who are on other medications with the potential to affect the course of asthma or to interact with sympathomimetic amines (e.g. beta blockers, oral decongestants, benzodiazepines, digitalis, phenothiazines, polycyclic antidepressants, monoamine oxidase inhibitors)

16. Subjects with a viral or bacterial upper or lower respiratory tract infection or sinus or middle ear infection within 4 weeks prior to the screening visit or during the run-in period

17. Subjects with any factors (e.g. infirmity, disability, or geographic location) that the investigator feel would likely limit the patient's compliance with the study protocol or scheduled clinic visits

18. Subjects who have used any investigational drug in any clinical trial within 1 month of receiving the first dose of OT329 Solis™ study medication

19. Subjects who cannot communicate reliably or who are unlikely to co-operate with the requirements of the study, in the opinion of the Investigator

20. Subjects with a milk protein allergy

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• OT329 (combination of fluticasone propionate and salmeterol xinafoate)
Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Solis dry powder inhaler
• Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)
Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Diskus dry powder inhaler
• Placebo
Placebo (lactose) administered via the Solis dry powder inhaler

Locations

Country	Name	City	State
United States	Oriel Investigative Site	Albuquerque	New Mexico
United States	Oriel Investigative Site	Anaheim	California
United States	Oriel Investigative Site	Austin	Texas
United States	Oriel Investigative Site	Austin	Texas
United States	Oriel Investigative Site	Bellevue	Nebraska
United States	Oriel Investigative Site	Centennial	Colorado
United States	Oriel Investigative Site	Charlotte	North Carolina
United States	Oriel Investigative Site	Cincinnati	Ohio
United States	Oriel Investigative Site	Cincinnati	Ohio
United States	Oriel Investigative Site	Clearwater	Florida
United States	Oriel Investigative Site	Coral Gables	Florida
United States	Oriel Investigative Site	Eugene	Oregon
United States	Oriel Investigative Site	Goodyear	Arizona
United States	Oriel Investigative Site	Homestead	Florida
United States	Oriel Investigative Site	Houston	Texas
United States	Oriel Investigative Site	Houston	Texas
United States	Oriel Investigative Site	Iowa City	Iowa
United States	Oriel Investigative Site	Jupiter	Florida
United States	Oriel Investigative Site	Kissimee	Florida
United States	Oriel Investigative Site	Lawrenceville	Georgia
United States	Oriel Investigative Site	Los Angeles	California
United States	Oriel Invetigative Site	Los Angeles	California
United States	Oriel Investigative Site	Medford	Oregon
United States	Oriel Investigative Site	Miami	Florida
United States	Oriel Investigative Site	Middleburg Heights	Ohio
United States	Oriel Therapeutics Site	Minneapolis	Minnesota
United States	Oriel Investigative Site	Mission Viejo	California
United States	Oriel Investigative Site	New Port Richie	Florida
United States	Oriel Investigative Site	New York	New York
United States	Oriel Investigative Site	North Dartmouth	Massachusetts
United States	Oriel Investigative Site	Oklahoma City	Oklahoma
United States	Oriel Investigative Site	Omaha	Nebraska
United States	Oriel Investigative Site	Orlando	Florida
United States	Oriel Investigative Site	Plano	Texas
United States	Oriel Investigative Site	Portland	Oregon
United States	Oriel Investigative Site	Providence	Rhode Island
United States	Oriel Investigative Site	Raleigh	North Carolina
United States	Oriel Investigative Site	Richmond	Virginia
United States	Oriel Investigative Site	Rock Hill	South Carolina
United States	Oriel Investigative Site	Skillman	New Jersey
United States	Oriel Investigative Site	St. Louis	Missouri
United States	Oriel Investigative Site	Tacoma	Washington
United States	Oriel Investigative Site	Tallahassee	Florida
United States	Oriel Investigative Site	Tempe	Arizona
United States	Oriel Investigative Site	Toledo	Ohio
United States	Oriel Investigative Site	Warwick	Rhode Island
United States	Oriel Investigative Site	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Oriel Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the serial FEV1-time curve (AUC 0-12h)		0-12 hours after dosing on Day 1	No
Primary	FEV1 trough		Post-4 weeks of treatment	No
Secondary	Adverse Events		From Screen (Day -28) until 1 week post last treatment	Yes